학술논문

Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions
Document Type
Academic Journal
Source
Journal of Asthma and Allergy. March 31, 2022, Vol. 15, p281, 22 p.
Subject
United States. Food and Drug Administration
Esophagitis -- Care and treatment
Amino acids
Language
English
ISSN
1178-6965
Abstract
Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE. Keywords: eosinophilic esophagitis, EoE, proton pump inhibitor medication, PPI, precision medicine
EoE Background EoE is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults (Figure 1). (4) It is a clinicopathologic disorder requiring a constellation of [...]